People
Meet Our Team
Monument Tx is led by a highly experienced team of executives with direct experience designing and managing hundreds of neuroscience clinical trials.
Dr Jenny Barnett
Co-Founder, Chief Executive Officer
Jenny brings a unique blend of commercial and scientific expertise to drive Monument’s mission to transform neuroscience through precision medicine. Previously Chief Scientific Officer at Cambridge Cognition, Jenny played a pivotal role in establishing Monument Tx as a successful spin-out, securing substantial funding to support its innovative solutions.
Jenny holds an MA in Experimental Psychology from Oxford University and a PhD in Schizophrenia Epidemiology from the University of Cambridge, followed by postdoctoral work at Massachusetts General Hospital and the Broad Institute of Harvard and MIT. She has published over 70 papers, holds six patents, and is an honorary member of Cambridge’s Department of Psychiatry.
Dr Kiri Granger
Co-Founder, Chief Scientific Officer
With 10 years of industry experience, Kiri is a highly regarded expert in the CNS field, particularly in schizophrenia. During her role as Director of Neuroscience at Cambridge Cognition, she was lead scientist on over 100 clinical trial programs and gained recognition for her innovative strategies that successfully demonstrated the efficacy of compounds following negative trial results.
During her PhD at the University of Nottingham, Kiri developed the biomarker that is now integral to Monument’s schizophrenia program, helping to establish the company’s precision medicine approach. She is an inventor on multiple patents and serves as Assistant Professor in the Department of Psychology at the University of Nottingham, reflecting her commitment to advancing research in neuroscience.
Sheryl Caswell
Co-Founder, Chief Development Officer
Robert Radie
Chair
Bob has more than three decades of executive experience in public and private pharmaceutical and biotech companies. Having been involved in the launch of blockbuster antidepressant and antipsychotic drugs for Eli Lilly early in his career, Bob has continued a focus in psychiatric and neurological therapeutics.
He led commercial and acquisition successes in neuroscience small molecule companies Prestwick Pharmaceuticals and Zyla Life Sciences (formerly Egalet), and now serves as CEO and Chair of nerve injury-focused Neuraptive Therapeutics.
Richard Bungay
Non-Exec Director
David Ford
Investor Director
Dr Paula Moran
Scientific Consultant
Steve Plant
CFO
Sheryl Caswell
Co-Founder, Chief Development Officer
Sheryl brings over 30 years of pharmaceutical development experience with expertise in advancing new, reformulated and repurposed compounds. She has successfully led global clinical development programs across a wide range of therapeutic areas, with a recent focus on working in small biotech companies.
Known for her strong track record in early-stage clinical research, Sheryl ensures that innovative products progress efficiently and strategically through development, expertly positioning them for regulatory and commercial success.
Robert Radie
Chair
Bob has more than three decades of executive experience in public and private pharmaceutical and biotech companies. Having been involved in the launch of blockbuster antidepressant and antipsychotic drugs for Eli Lilly early in his career, Bob has continued a focus in psychiatric and neurological therapeutics.
He led commercial and acquisition successes in neuroscience small molecule companies Prestwick Pharmaceuticals and Zyla Life Sciences (formerly Egalet), and now serves as CEO and Chair of nerve injury-focused Neuraptive Therapeutics.
Richard Bungay
Non-Exec Director
David Ford
Non-Exec Director
David is an active life sciences angel investor and a former Managing Director for Prudential Capital Group and Intermediate Capital Group.
Dr Paula Moran
Scientific Consultant
Paula is a pioneering research scientist and an honorary Associate Professor at the University of Nottingham. Following a PhD from the National University of Ireland she has had academic roles at the Institute of Psychiatry, Kings College London and University of Nottingham, where she led collaborations with several pharmaceutical industry partners.
She is best known for her translational research on abnormal information processing.
Steve Plant
CFO
Steve is an experienced Finance Director specialising in working with early-stage SMEs in the UK tech/healthcare sector. He qualified as a Chartered Accountant in Manchester with KPMG and after qualifying joined a UK-wide retail business where he held a number of roles.
He then moved into international retail as Finance Director for new business start-ups in Russia and India. On returning to the UK Steve has held a variety of Financial Director roles in customer facing businesses across a broad range of industry sectors.
Meet Our Advisory Board
Dr Mark Treherne
Co-Founder, Chair of Advisory Board
Dr Jeff Baker
Jeff Baker, PhD, has worked in the pharmaceutical industry for over twenty years. He has led or contributed to clinical trials evaluating novel mechanism molecules for cognition in schizophrenia, Alzheimer’s disease, and ADHD.
Dr Stephen Brannan
Professor Ed Bullmore
Head of the Department of Psychiatry, University of Cambridge. Ed has authored more than 500 publications, has 15 years’ experience in the pharmaceutical industry and is the author of “The Inflamed Mind.”
Dr Robert Gristwood
Founder and Chief Scientist at Acacia Pharma. Robert has worked within the pharmaceutical industry for more than 30 years’ and been responsible for many innovative products.
Dr Heather Preston
Dr Preston brings over 20 years of experience as a healthcare venture capitalist. She has a longstanding interest in developing better treatments for schizophrenia and served on the Board of Karuna Therapeutics prior to their successful acquisition by Bristol Myers Squibb for $14 billion in 2024.
Dr Steven Powell
Professor Trevor Robbins
Dr Michael Sand
Michael has 35 years’ experience in the pharmaceutical industry, focused on developing novel compounds for serious mental illness. He currently serves as an Independent Consultant to the NIMH.
Dr Robert Gristwood
Founder and Chief Scientist at Acacia Pharma. Robert has worked within the pharmaceutical industry for more than 30 years’ and been responsible for many innovative products.
Dr Heather Preston
Dr Preston brings over 20 years of experience as a healthcare venture capitalist. She has a longstanding interest in developing better treatments for schizophrenia and served on the Board of Karuna Therapeutics prior to their successful acquisition by Bristol Myers Squibb for $14 billion in 2024.
Dr Steven Powell
Steven graduated in microbiology from the University of Wales and was awarded a PhD from the University of Aberdeen. He has over thirty years operational and investment experience in pharmaceutical and healthcare companies in the UK, USA and Scandinavia.
Professor Trevor Robbins
Professor of Cognitive Neuroscience and former Head of the Department of Psychology at the University of Cambridge.
Dr Michael Sand
Michael has 35 years’ experience in the pharmaceutical industry, focused on developing novel compounds for serious mental illness. He currently serves as an Independent Consultant to the NIMH.
